Heart drug may unlock safe exercise for cardiomyopathy patients
NCT ID NCT07077005
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 22 times
Summary
This study looks at whether adding a structured exercise program is safe and helpful for people with hypertrophic obstructive cardiomyopathy who are already taking the drug mavacamten. About 24 adults with mild symptoms will either do supervised endurance and strength training for 6 weeks or continue their usual care. Researchers will track side effects, fitness levels, heart function, and quality of life to see if exercise can be a safe addition to their treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOMYOPATHY, HYPERTROPHIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Technical University Munich
RECRUITINGMunich, Bavaria, 81675, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.